Novartis presents new patient-reported outcomes data from NATALEE trial

Novartis presented new patient-reported outcomes data from the Phase III NATALEE trial at the European Society for Medical Oncology, or ESMO, Virtual Plenary. The data show that a broad population of patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer maintained health-related quality of life during treatment with Kisqali plus endocrine therapy, the company announced. Further analysis of the NATALEE trial is ongoing, and additional data will be shared at upcoming medical meetings. “No patient should have to choose between maintaining their quality of life and doing everything they can to remain cancer free. These patient-reported outcomes add to the wealth of efficacy and tolerability data from the NATALEE trial suggesting Kisqali is a potential adjuvant treatment of choice for a broad range of patients with HR+/HER2- EBC, including those with node-negative disease. Kisqali could enable patients with EBC to live well with greater peace of mind,” said Jeff Legos, Executive Vice President, Global Head of Oncology and Hematology Development at Novartis.